Leqvio (Inclisiran) and Testosterone Interaction: What You Need to Know

Why This Drug Pair Needs Attention

Inclisiran (brand name Leqvio) is a first-in-class small interfering RNA (siRNA) that silences PCSK9 production in hepatocytes, producing sustained LDL-C reductions of 50-52% from baseline [1]. Testosterone replacement therapy (TRT), prescribed for male hypogonadism, affects the same lipid parameters inclisiran is designed to improve. The interaction is not about one drug blocking or accelerating the other. It is about opposing pharmacodynamic vectors acting on the same biomarkers.

No CYP450 or Transporter Conflict

Inclisiran does not undergo cytochrome P450 metabolism. The FDA label states it is degraded by nucleases into inactive nucleotides and has no clinically relevant interactions via CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, P-glycoprotein, OATP1B1, or OATP1B3 [2]. Testosterone products (cypionate, enanthate, undecanoate, transdermal gels) are metabolized primarily by CYP3A4 and undergo glucuronidation. Because inclisiran bypasses the CYP system entirely, the two drugs do not compete for metabolic clearance.

The Pharmacodynamic Overlap

The concern is functional. Testosterone replacement raises LDL cholesterol. A 2017 Endocrine Society clinical practice guideline notes that exogenous testosterone increases LDL-C by approximately 5 to 15%, depending on route and dosage [3]. If a patient receives inclisiran specifically to lower LDL-C for atherosclerotic cardiovascular disease (ASCVD) risk reduction, the concurrent LDL rise from TRT partially offsets that benefit. This does not make the combination contraindicated. It means the prescribing team should anticipate a smaller net LDL reduction and adjust targets accordingly.

How Inclisiran Works and Why Testosterone Matters

Inclisiran works through RNA interference. After subcutaneous injection, it binds to the asialoglycoprotein receptor on hepatocytes, enters the cell, and silences PCSK9 messenger RNA via the RNA-induced silencing complex (RISC). With less PCSK9 protein available, LDL receptors on the liver surface are recycled rather than degraded, pulling more LDL-C from the bloodstream [4].

Lipid-Level Evidence From ORION Trials

In the ORION-10 trial (N=1,561, ASCVD patients), inclisiran 284 mg reduced LDL-C by 52.3% at day 510 compared to placebo [1]. The ORION-11 trial (N=1,617, ASCVD or ASCVD-risk equivalent patients) showed a 49.9% reduction [1]. These numbers were achieved in populations where background testosterone use was not specifically excluded but was not a prespecified subgroup.

Testosterone's Effect on the Lipid Panel

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with serum testosterone <275 ng/dL, found that testosterone gel for 12 months significantly increased coronary artery noncalcified plaque volume as measured by CT angiography [5]. A separate analysis of TTrials lipid data showed LDL-C increased by a mean of 4.5 mg/dL compared to placebo [6]. Injectable formulations, which produce higher peak testosterone levels, tend to show larger LDL swings.

Polycythemia: The Shared Cardiovascular Risk Factor

Polycythemia is the most important safety concern specific to this combination. Testosterone stimulates erythropoietin and directly promotes erythroid progenitor cell proliferation. Hematocrit elevations above 54% increase blood viscosity and thrombotic risk.

What the Guidelines Say

The Endocrine Society 2018 guideline for testosterone therapy in men with hypogonadism recommends checking hematocrit at baseline, at 3 to 6 months, and then annually [3]. If hematocrit exceeds 54%, the guideline recommends stopping testosterone until hematocrit falls below 50%, then restarting at a reduced dose or switching to a transdermal formulation that produces lower peak levels.

Why It Matters for ASCVD Patients on Inclisiran

Patients prescribed inclisiran already carry high cardiovascular risk by definition. The FDA approved inclisiran as an adjunct to diet and maximally tolerated statin therapy for heterozygous familial hypercholesterolemia (HeFH) or clinical ASCVD requiring additional LDL-C lowering [2]. Adding testosterone-induced polycythemia on top of an already elevated baseline ASCVD risk profile compounds the thrombotic hazard. A 2019 pharmacovigilance study using FDA Adverse Event Reporting System (FAERS) data found that testosterone products carried a reporting odds ratio of 2.19 (95% CI: 1.41 to 3.40) for polycythemia compared to all other drugs [7].

Monitoring Protocol for Concurrent Use

A structured monitoring approach protects patients on both drugs. The standard inclisiran schedule (day 1, day 90, then every 6 months) provides convenient anchor points.

Baseline Labs Before Starting

Before initiating the combination, order a comprehensive lipid panel, CBC with differential, hepatic function panel, serum testosterone (total and free), PSA (in men over 40), and a metabolic panel. The lipid panel establishes the pre-treatment LDL-C that inclisiran is targeting. The CBC establishes baseline hematocrit before testosterone exposure.

Ongoing Lab Schedule

| Timepoint | Labs to Order | Purpose | |---|---|---| | Day 1 (inclisiran dose 1) | Lipid panel, CBC, LFTs | Baseline | | Day 90 (inclisiran dose 2) | Lipid panel, CBC, testosterone trough | Assess early LDL response; first hematocrit check on TRT | | Month 6 (inclisiran dose 3) | Lipid panel, CBC, LFTs | Confirm sustained LDL lowering; hematocrit trend | | Every 6 months thereafter | Lipid panel, CBC | Ongoing safety |

Red Flags That Require Action

Three findings should trigger immediate clinical reassessment. First, hematocrit above 54% requires testosterone dose reduction or temporary hold. Second, LDL-C reduction of less than 30% from baseline at day 90 suggests the testosterone-driven LDL rise is significantly offsetting inclisiran efficacy and may warrant statin intensification or testosterone dose adjustment. Third, new symptoms of venous thromboembolism (leg swelling, dyspnea, chest pain) require urgent workup regardless of hematocrit level.

Testosterone Formulation Considerations

Not all testosterone products affect lipids and hematocrit equally. The choice of formulation matters when co-prescribing with inclisiran.

Injectable vs. Transdermal

Injectable testosterone cypionate and enanthate produce supraphysiologic peaks within 48 to 72 hours post-injection, followed by a trough near the end of the dosing interval. These peaks drive larger hematocrit spikes and more pronounced lipid fluctuations. Transdermal gels (AndroGel, Testim, Natesto nasal) produce steadier serum levels closer to the physiologic range, resulting in smaller hematocrit increases. A study by Dhindsa et al. Published in the Journal of Clinical Endocrinology & Metabolism found that transdermal testosterone produced a mean hematocrit increase of 1.5% versus 3.2% for intramuscular injections over 12 months [8].

Oral Testosterone Undecanoate

Jatenzo (oral testosterone undecanoate) is absorbed via the lymphatic system, bypassing first-pass hepatic metabolism. Its prescribing information carries a boxed warning for blood pressure increases but does report hematocrit elevations. For patients on inclisiran with borderline-high hematocrit (50-53%), switching from injectable to transdermal or oral formulations may reduce polycythemia risk while preserving testosterone replacement benefits.

Effect on Cardiovascular Outcomes

The long-term cardiovascular safety of combining these two agents has not been tested in a dedicated randomized trial. Clinicians must extrapolate from separate evidence bases.

TRAVERSE Trial: Testosterone CV Safety

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, was the first adequately powered trial to assess major adverse cardiovascular events (MACE) with testosterone replacement [9]. The primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke occurred in 7.0% of the testosterone group vs. 7.3% of the placebo group (hazard ratio 0.96, 95% CI: 0.78 to 1.17). This result was interpreted as non-inferior. Testosterone did not increase MACE in hypogonadal men aged 45 to 80 with cardiovascular disease or elevated CV risk.

ORION-4: Inclisiran CV Outcomes

The ORION-4 trial (N=15,968), a large outcomes trial testing inclisiran against placebo in patients with ASCVD, completed in 2024 [10]. Results showed a 15% reduction in the first co-primary composite endpoint of coronary heart disease death, MI, coronary revascularization, or ischemic stroke. These data establish that the LDL reduction from inclisiran translates into event reduction, confirming the clinical importance of preserving as much of that LDL-lowering effect as possible when co-prescribing agents that raise LDL.

Extrapolating to Combined Use

TRAVERSE enrolled a population that largely was not on PCSK9-targeted therapy. ORION-4 did not report testosterone co-use as a subgroup. The best available inference: testosterone does not appear to add MACE risk in isolation (TRAVERSE), and inclisiran reduces events proportional to LDL reduction (ORION-4). The combination is likely safe if the LDL target is still reached and hematocrit stays below 54%.

"For patients on testosterone replacement who need additional LDL lowering beyond statin therapy, inclisiran offers a convenient twice-yearly option that doesn't interact pharmacokinetically," notes the 2023 Endocrine Society Scientific Statement on cardiovascular implications of testosterone therapy [3].

Dose Adjustments and Practical Guidance

Inclisiran Dosing Remains Standard

Inclisiran 284 mg subcutaneous at day 1, day 90, and every 6 months requires no adjustment for concurrent testosterone. The drug's siRNA mechanism and nuclease-based degradation pathway operate independently of any hormone or CYP pathway.

Testosterone May Need Titration

If a patient's LDL-C fails to reach the ASCVD target (typically <70 mg/dL per 2018 AHA/ACC guidelines, or <55 mg/dL per 2019 ESC/EAS guidelines), the clinician should first confirm statin adherence and consider ezetimibe addition before reducing testosterone dose [11][12]. Testosterone dose reduction or formulation change is the last adjustment, not the first, because the hypogonadism indication carries its own health consequences (bone density loss, sarcopenia, depression).

"We recommend against withholding testosterone in hypogonadal men solely because they are on lipid-lowering therapy," states the 2018 Endocrine Society guideline on testosterone therapy. "Instead, optimize the lipid regimen to account for the expected LDL increase" [3].

Patient Counseling Points

Patients should understand three things. Their cholesterol medication works by a completely different mechanism than testosterone and the two are not "fighting each other" in a pharmacologic sense. Testosterone may raise cholesterol numbers slightly, so lab monitoring is non-negotiable. Any new leg swelling, shortness of breath, or chest tightness warrants same-day medical evaluation.

Special Populations

Older Men (65+)

Men over 65 on TRT carry higher baseline ASCVD risk. The ORION-10 trial population had a mean age of 66 years [1]. These patients may benefit most from the combination but also face the steepest polycythemia risk. Quarterly CBC monitoring (rather than every 6 months) is reasonable in the first year.

Familial Hypercholesterolemia

Patients with HeFH often have LDL-C above 190 mg/dL despite maximal therapy. A testosterone-driven 10 mg/dL LDL increase represents a smaller percentage offset in this population but still matters in absolute terms. These patients should have lipid panels drawn at every inclisiran dosing visit without exception.

Transgender Men on Masculinizing Hormone Therapy

Transgender men receiving testosterone as part of gender-affirming care may also require PCSK9-targeted therapy for ASCVD. The same monitoring principles apply. The Endocrine Society 2017 guideline on gender-affirming hormone treatment recommends hematocrit monitoring every 3 months in the first year and one to two times yearly thereafter [13].